SCT, secretin, 6343

N. diseases: 230; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0043515
Disease: Zollinger-Ellison syndrome
Zollinger-Ellison syndrome 		0.020 Biomarker disease BEFREE We present the history of a 48-year-old man with primary hyperparathyroidism and Zollinger-Ellison syndrome who underwent acid secretory studies and secretin stimulation tests before and after parathyroidectomy. 3798319 1987
CUI: C0039231
Disease: Tachycardia
Tachycardia 		0.300 Biomarker phenotype CTD_human Secretin increased heart rate by 14 beats/min (20% above base-line) and this also was not altered by propranolol pretreatment. 2103752 1990
CUI: C0080203
Disease: Tachyarrhythmia
Tachyarrhythmia 		0.300 Biomarker phenotype CTD_human Effect of propranolol on secretin-induced gastrin release and secretin-induced tachycardia in patients with the Zollinger-Ellison syndrome. 2103752 1990
CUI: C0267834
Disease: Liver cyst
Liver cyst 		0.010 Biomarker disease BEFREE Within 8 min of the intravenous administration of secretin, secretion of fluid increased in two of three hepatic cysts and in the renal cyst. 1970324 1990
CUI: C0268800
Disease: Simple renal cyst
Simple renal cyst 		0.010 Biomarker disease BEFREE Within 8 min of the intravenous administration of secretin, secretion of fluid increased in two of three hepatic cysts and in the renal cyst. 1970324 1990
CUI: C3887499
Disease: Renal cyst
Renal cyst 		0.010 Biomarker phenotype BEFREE Within 8 min of the intravenous administration of secretin, secretion of fluid increased in two of three hepatic cysts and in the renal cyst. 1970324 1990
CUI: C0027809
Disease: Neurilemmoma
Neurilemmoma 		0.010 Biomarker disease BEFREE In the current study, SCT-1 cells, a Schwannoma cell line derived from a transgenic mouse, were transfected with a human NGF (hNGF) cDNA. 7728338 1995
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.040 Biomarker disease BEFREE Renal function and renotropic effects of secretin in cystic fibrosis. 9348270 1997
CUI: C0004352
Disease: Autistic Disorder
Autistic Disorder 		0.330 Biomarker disease BEFREE The study of the transcriptional control of human secretin and its receptor should shed light on the pathological developments of pancreatic cancer and autism in the future. 10437774 1999
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 AlteredExpression disease BEFREE The study of the transcriptional control of human secretin and its receptor should shed light on the pathological developments of pancreatic cancer and autism in the future. 10437774 1999
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 Biomarker disease BEFREE The KRM incidence was found to be relatively high for the patients with PCa and BTCa by MASA, which is a highly sensitive method, although the incidence of KRM in DA from the patients with PCa was not as high as the incidence in their PPJ with secretin stimulation. 10526271 1999
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.090 AlteredExpression disease BEFREE The study of the transcriptional control of human secretin and its receptor should shed light on the pathological developments of pancreatic cancer and autism in the future. 10437774 1999
CUI: C0947622
Disease: Cholecystolithiasis
Cholecystolithiasis 		0.010 Biomarker disease BEFREE DA was collected endoscopically without secretin stimulation immediately after the ERCP procedure from 160 patients: 38 patients with PCa, 38 with chronic pancreatitis (CP), 22 with BTCa, 20 with adenomyomatosis of the gallbladder (AGB), 22 with cholecystolithiasis (CCL), and 20 control subjects. 10526271 1999
CUI: C1852438
Disease: CATARACT, COPPOCK-LIKE
CATARACT, COPPOCK-LIKE 		0.010 GeneticVariation disease BEFREE DA was collected endoscopically without secretin stimulation immediately after the ERCP procedure from 160 patients: 38 patients with PCa, 38 with chronic pancreatitis (CP), 22 with BTCa, 20 with adenomyomatosis of the gallbladder (AGB), 22 with cholecystolithiasis (CCL), and 20 control subjects. 10526271 1999
CUI: C4745063
Disease: Biliary Tract Carcinoma
Biliary Tract Carcinoma 		0.010 GeneticVariation disease BEFREE The KRM incidence was found to be relatively high for the patients with PCa and BTCa by MASA, which is a highly sensitive method, although the incidence of KRM in DA from the patients with PCa was not as high as the incidence in their PPJ with secretin stimulation. 10526271 1999
CUI: C0023467
Disease: Leukemia, Myelocytic, Acute
Leukemia, Myelocytic, Acute 		0.100 Biomarker disease BEFREE In conclusion our study could provide some guidelines for AML therapy: (1) patients in the 'favorable' karyotype group seem to have a longer DFS when treated with an intensive induction/consolidation regimen, adopted before auto-SCT instead of standard induction; this underlines the importance of reinforcement of chemotherapy, not necessarily based on repeated high-dose AraC cycles. 11417475 2001
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.100 Biomarker disease BEFREE In this issue of the European Journal of Gastroenterology and Hepatology, Boadas et al. collected pancreatic juice following secretin stimulation at the time of ERCP, and detected K-ras in 44% of patients with pancreatic cancer. 11711767 2001
CUI: C0856825
Disease: Acute GVH disease
Acute GVH disease 		0.100 Biomarker disease BEFREE Four patients died after allo-SCT during the study period from either acute GVHD (grade IV), pneumonitis, gastrointestinal bleeding or renal insufficiency. 11244433 2001
CUI: C0023465
Disease: Acute monocytic leukemia
Acute monocytic leukemia 		0.090 Biomarker disease BEFREE In conclusion our study could provide some guidelines for AML therapy: (1) patients in the 'favorable' karyotype group seem to have a longer DFS when treated with an intensive induction/consolidation regimen, adopted before auto-SCT instead of standard induction; this underlines the importance of reinforcement of chemotherapy, not necessarily based on repeated high-dose AraC cycles. 11417475 2001
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.090 Biomarker disease BEFREE In this issue of the European Journal of Gastroenterology and Hepatology, Boadas et al. collected pancreatic juice following secretin stimulation at the time of ERCP, and detected K-ras in 44% of patients with pancreatic cancer. 11711767 2001
CUI: C0002895
Disease: Anemia, Sickle Cell
Anemia, Sickle Cell 		0.040 Biomarker disease BEFREE The situation with SCT is different; there will continue to be the identification of parents who have the potential for having a child with a sickle cell disease but because they will not be tested or counseled, there will continue to be a population of children with a sickle cell disease whose parents have not been enabled to make informed decisions that they believe are in their best interest relative to family planning. 11499064 2001
CUI: C0010674
Disease: Cystic Fibrosis
Cystic Fibrosis 		0.040 AlteredExpression disease BEFREE There were significant increases in CF intestinal mRNA levels for secretin (310% of normal, P < 0.001) and vasoactive intestinal peptide (148% of normal, P < 0.05). 11557509 2001
CUI: C1848934
Disease: SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME
SPONDYLOCARPOTARSAL SYNOSTOSIS SYNDROME 		0.030 Biomarker disease BEFREE Patients receiving allo-SCT had significantly longer DFS (P = 0.005); in particular, allo-SCT significantly improved DFS in the 'favorable' and 'intermediate' groups (P = 0.04 and P = 0.048, respectively). 11417475 2001
CUI: C0023493
Disease: Adult T-Cell Lymphoma/Leukemia
Adult T-Cell Lymphoma/Leukemia 		0.010 Biomarker disease BEFREE These results strongly suggest that allo-SCT may improve the survival in ATL if a controlled degree of GVHD develops. 11244433 2001
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.010 Biomarker group BEFREE All lymphomas occurred in the setting of allo-SCT and had a rapid clinical course. 11502981 2001